Stentys develops and markets innovative solutions used to treat patients presenting complex coronary conditions. Stentys’ self-apposing stents are designed to adapt to arteries with ambiguous vessel diameters or with areas of vessel diameter fluctuations so as to avoid the mal-apposition issues associated with conventional stents. The Apposition III clinical study showed a very low 1-year mortality rate among 1,000 high-risk patients treated for myocardial infarction, compared with recent studies on conventional stents.
October 2010: Stentys (STNT) successfully raised €22.7 million in an IPO.
Market capitalisation at IPO date: €87 million